Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Johnson & Johnson (JNJ)

Pharmaceutical Preparations · New Brunswick, NJ

Our rating: Neutral

Neutral reaffirmed at $267.61, moderate conviction, October 22, 2026.

Breaks if: The Neutral call turns Cautious if reported revenue growth slows below 3% for two consecutive quarters, or if annual free cash flow falls below $16B — either condition would indicate litigation outflows or volume erosion are biting harder than the current figures imply. It turns Positive if free cash flow closes to within 10% of net income for two straight quarters while top-line growth holds above 7% — the clearest combination signaling that the cash drag is easing and the franchise is compounding cleanly.

Key figures

Market value$651.1B
Revenue, last 12 months$99.3B
Net income, last 12 months$16.1B
Free cash flow, last 12 months$20.6B
Price to earnings40.5×
Free cash flow yield3.2%
Dividend yield2.0%
Operating marginn/a
Return on equity20.0%
Beta to the S&P 500−0.01
Volatility, annualized19.5%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 27, 2026$25.4B5.9%$0.09$6.4B
June 28, 2026$25.3B6.6%$2.27$7.3B
March 29, 2026$24.1B9.9%$2.14$1.5B
December 28, 2025$24.6B9.1%$2.09$5.5B
September 28, 2025$24.0B6.8%$2.12$8.0B
June 29, 2025$23.7B5.8%$2.29$2.8B
March 30, 2025$21.9B2.4%$4.54$3.4B
December 29, 2024$22.5B5.3%$1.41$5.4B

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

17 ledger entries and 27 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.